VivoSeq
Infectious Disease

Common Cold

40

Pipeline Programs↗

1

Active Trials↗

19

Companies Involved↗

Common Cold is a moderately active landscape with 40 programs across 19 companies. The most active players are Xeris Pharmaceuticals, Johnson & Johnson Consumer Inc. (J&JCI), Merck & Co.. 12 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

0/100

Mech. Concentration

27/100

Completion Rate

82/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

X

Xeris Pharmaceuticals

1 program

Phase 1J

Johnson & Johnson Consumer Inc. (J&JCI)

2 programs

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2Pfizer logo

Pfizer

2 programs

Phase 3A

Arbor Pharmaceuticals, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

98%

Small molecule

51 of 52 classified programs — the dominant modality here.

2%ALL OTHERSProtein / enzyme12%

Small molecule leads; the ring shows all 52 classified programs, each share of the total. Modality classified for 100% of 52 pipeline programs.

Analysis

Trial Status

41

clinical trials

Completed28 · 68%
Unknown status6 · 15%
Withdrawn4 · 10%
Terminated1 · 2%
Suspended1 · 2%
Recruiting1 · 2%

Clinical Trials

Trial Activity

41 trials

A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold
Recruiting·Tasly Pharmaceutical Group Co., Ltd logoTasly Pharmaceutical Group Co., Ltd·Phase 3·NCT06697886·480 enrolled
Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00394914·311 enrolled
Evaluation of Echinacea for the Common Cold
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00032500
The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.
Completed·GSK logoGSK·Phase 4·NCT02246166·53 enrolled
Placebo and Active Controlled Study to Compare the Efficacy of Aspirin and Paracetamol in Treatment of Sore Throat Associated With a Common Cold
Completed·Bayer logoBayer·Phase 4·NCT01465009·508 enrolled
Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu
Completed·HHospital de Clinicas de Porto Alegre·Phase 3·NCT01158326·216 enrolled
Efficacy and Safety of Sinutab on Subjects in the Setting of a Common Cold
Completed·MMcNeil AB·Phase 4·NCT00378144·469 enrolled
Effect of Paracetamol on the Common Cold
Completed·GSK logoGSK·Phase 2·NCT01277081·200 enrolled
Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)
Completed·NNycomed·N/A·NCT00480194·1,000 enrolled
Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
Completed·Novartis logoNovartis·Phase 3·NCT01448057·341 enrolled
A Study of Nasal Glucagon in Participants With a Common Cold
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02778100·36 enrolled
Effects of Two Doses of a Common Cold Treatment on Alertness
Completed·GSK logoGSK·Phase 3·NCT01686646·240 enrolled
To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold
Completed·GSK logoGSK·Phase 2·NCT03005067·171 enrolled
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
Completed·SSynairgen Research Ltd.·Phase 2·NCT03570359·122 enrolled
Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold
Completed·Bayer logoBayer·Phase 3·NCT01361399·1,088 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)